Sudarshan Pharma Industries Ltd
Incorporated in 2008, Sudarshan Pharma Industries Ltd manufactures API and Pharmaceutical Items. It also trades in Chemicals and Solvents[1]
- Market Cap ₹ 722 Cr.
- Current Price ₹ 30.0
- High / Low ₹ 35.2 / 18.5
- Stock P/E 31.0
- Book Value ₹ 6.44
- Dividend Yield 0.00 %
- ROCE 15.1 %
- ROE 16.3 %
- Face Value ₹ 1.00
Pros
- Company is expected to give good quarter
- Company has delivered good profit growth of 54.2% CAGR over last 5 years
- Company's working capital requirements have reduced from 43.0 days to 17.1 days
Cons
- Stock is trading at 4.65 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Commodities Chemicals Chemicals & Petrochemicals Specialty Chemicals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| 148 | 193 | 357 | 461 | 464 | 505 | 703 | |
| 143 | 186 | 346 | 446 | 441 | 465 | 652 | |
| Operating Profit | 5 | 7 | 11 | 15 | 23 | 40 | 51 |
| OPM % | 3% | 4% | 3% | 3% | 5% | 8% | 7% |
| 0 | 0 | 0 | 1 | 3 | -0 | 9 | |
| Interest | 3 | 3 | 3 | 5 | 9 | 16 | 26 |
| Depreciation | 0 | 1 | 1 | 1 | 1 | 2 | 4 |
| Profit before tax | 2 | 4 | 7 | 9 | 15 | 22 | 31 |
| Tax % | 26% | 25% | 26% | 26% | 25% | 26% | 23% |
| 1 | 3 | 5 | 7 | 11 | 16 | 23 | |
| EPS in Rs | 0.13 | 0.28 | 0.54 | 0.29 | 0.48 | 0.66 | 0.97 |
| Dividend Payout % | 0% | 0% | 0% | 10% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 29% |
| 3 Years: | 15% |
| TTM: | 39% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 54% |
| 3 Years: | 48% |
| TTM: | 29% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 63% |
| 1 Year: | 0% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 14% |
| 3 Years: | 14% |
| Last Year: | 16% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 10 | 10 | 10 | 24 | 24 | 24 | 24 |
| Reserves | 10 | 13 | 20 | 77 | 88 | 107 | 131 |
| 21 | 30 | 31 | 34 | 105 | 171 | 285 | |
| 18 | 47 | 77 | 97 | 67 | 100 | 202 | |
| Total Liabilities | 58 | 99 | 138 | 232 | 283 | 402 | 642 |
| 6 | 6 | 6 | 20 | 26 | 24 | 104 | |
| CWIP | 0 | 0 | 1 | 0 | 2 | 6 | 3 |
| Investments | 0 | 0 | 0 | 12 | 14 | 30 | 0 |
| 53 | 93 | 131 | 200 | 242 | 342 | 534 | |
| Total Assets | 58 | 99 | 138 | 232 | 283 | 402 | 642 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| 1 | 3 | -4 | -29 | 8 | 35 | -2 | |
| -3 | -1 | -1 | -26 | -7 | -20 | -78 | |
| -0 | -1 | 4 | 66 | -12 | -14 | 79 | |
| Net Cash Flow | -2 | -0 | -1 | 11 | -12 | 0 | -1 |
| Free Cash Flow | -4 | 1 | -5 | -43 | 4 | 30 | -51 |
| CFO/OP | 20% | 50% | -19% | -179% | 43% | 96% | 7% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 66 | 114 | 75 | 64 | 96 | 116 | 121 |
| Inventory Days | 46 | 49 | 51 | 63 | 74 | 117 | 129 |
| Days Payable | 40 | 91 | 80 | 78 | 49 | 76 | 111 |
| Cash Conversion Cycle | 72 | 72 | 46 | 50 | 122 | 156 | 139 |
| Working Capital Days | 35 | 29 | 27 | 54 | 59 | 53 | 17 |
| ROCE % | 15% | 19% | 15% | 14% | 16% | 15% |
Insights
In beta| Mar 2016 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Number of Permanent Employees Number ・Standalone data |
|
||||
| Trade Receivables Turnover Ratio Times |
|||||
| Number of Countries with Export Presence Number |
|||||
| Number of States with Ethical Marketing Reach Number |
|||||
| Number of Approved Products (Domestic & Export) Number |
|||||
| Number of Medical Practitioners Associated Number |
|||||
| Palghar Unit - Daily Output (Single Shift) Litres |
|||||
| Palghar Unit - Oral Liquid Manufacturing Tank Capacity Litres |
|||||
| Ratna Lifesciences - Oncology API Capacity Metric Tonnes p.a. |
|||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Investor Presentation
2m - As per Regulation 30 read with Para A of Part A of Schedule III to SEBI (LODR) Regulations, 2015, we hereby submit the updated Investor …
-
Board Meeting Outcome for Approval Of Upto U.S. $ 20,000,000 Of 8.00% Senior Unsecured Foreign Currency Convertible Bonds Due 2029 Of Sudarshan Pharma Industries Limited
1h - Board approved up to USD 20 million 8% FCCBs due 2029; issue opens May 18, 2026.
-
Board Meeting Intimation for Meeting To Be Held On Friday, May 15, 2026
12 May - Board meets 15 May 2026 to consider FCCB issuance, subject to approvals.
-
Announcement under Regulation 30 (LODR)-Resignation of Chief Financial Officer (CFO)
8 May - Sachin Mehta resigned as CFO effective 1 May 2026, but continues as Joint Managing Director.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
4 May - The newspaper advertisement for the Audited Standalone and Consolidated Financial Results for the quarter and financial year ended 31-03-2026 published in (i) Mumbai Lakshdeep (Marathi) …
Business Overview:[1][2]
SPIL does jobwork manufacturing in pharmaceutical Items and trading in chemicals and solvents in India. It
specializes in a host of products from rock chemicals intermediates and API to finish formulations and fully
integrated pharmaceutical and chemicals